ELVN (Nasdaq) selling holders report proposed sale, recent 272,322-share disposition

Rhea-AI Filing Summary

ELVN notice of proposed sale of Common Stock under Rule 144 by selling holders, reporting broker allocations and recent dispositions.

The filing lists a proposed sale of 833,800 shares (dated 02/23/2023), broker entries showing 787,024 and 46,776 shares, and a recent reported sale of 272,322 shares on 06/15/2026 for $12,259,936.44. The excerpt shows total shares outstanding as 69,822,989 as of 06/22/2026.

Insights

Securities Compliance Attorney

Rule 144 sale notice lists proposed and recent sales without proceeds recipient detail.

The filing documents a proposed sale of 833,800 shares and a recorded disposition of 272,322 shares on 06/15/2026 for $12,259,936.44. It includes broker entries and an outstanding share count of 69,822,989 as of 06/22/2026.

Timing, exact beneficial sellers for each broker allocation, and whether resale is subject to holding-period or other conditions are not detailed in the excerpt; subsequent filings or broker confirmations would clarify transfer mechanics.

Equity Markets Analyst

Reported disposals create potential near-term supply but are routine Rule 144 transactions.

The excerpt shows broker-allocated lots with Jefferies at 787,024 shares and Morgan Stanley at 46,776 shares, and a recent sale by a holder of 272,322 shares for $12,259,936.44. These entries document executed or proposed resale activity rather than company actions.

Market impact will depend on whether holders actually sell listed amounts; the filing does not specify execution method, timing, or whether sales are part of scheduled liquidity plans.

Key Figures

Proposed shares to be sold: 833,800 shares Broker allocation - Jefferies: 787,024 shares Broker allocation - Morgan Stanley: 46,776 shares +3 more

6 metrics

Proposed shares to be sold 833,800 shares dated 02/23/2023 (listed under Securities To Be Sold)

Broker allocation - Jefferies 787,024 shares Jefferies row with amount and proceeds $36,171,623.04, as of 06/22/2026

Broker allocation - Morgan Stanley 46,776 shares Morgan Stanley row with amount and proceeds $2,149,824.96, as of 06/22/2026

Shares sold in past 3 months 272,322 shares OrbiMed Private Investments VII, LP sale on 06/15/2026

Proceeds reported for recent sale $12,259,936.44 Proceeds tied to the 272,322-share sale on 06/15/2026

Shares outstanding 69,822,989 shares listed with broker rows as of 06/22/2026

Key Terms

Rule 144, Common Stock, Proposed sale, Selling holder

4 terms

Rule 144 regulatory

"notice of proposed sale of Common Stock under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Common Stock financial

"Securities Information | Common Stock | Jefferies LLC"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Proposed sale regulatory

"Securities To Be Sold | Common Stock | 02/23/2023 | Merger | Issuer"

Selling holder financial

"OrbiMed Private Investments VII, LP | Common Stock | 06/15/2026"

FAQ

What does the ELVN Form 144 filing report?

The filing reports proposed and recent sales of Common Stock, including a proposed sale of 833,800 shares and a sale of 272,322 shares on 06/15/2026 for $12,259,936.44. It lists broker allocations and an outstanding share count.

Who sold shares according to the ELVN excerpt?

The excerpt names a selling holder, OrbiMed Private Investments VII, LP, reporting a sale of 272,322 shares on 06/15/2026 for $12,259,936.44. Broker rows show allocations to Jefferies and Morgan Stanley.

How many ELVN shares are shown outstanding in the filing?

The excerpt shows 69,822,989 shares outstanding as of 06/22/2026. That figure appears with broker allocation rows and provides a reference point for outstanding capital stock.

Does the Form 144 excerpt state how sales will be executed?

No; the provided excerpt lists proposed and recent share amounts and broker entries but does not specify execution methods, timing, or whether sales were via block trades, open-market transactions, or private placements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 08:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001055951
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 Lookout Road Boulder COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	OrbiMed Private Investments VII, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Jefferies LLC 520 Madison Ave New York NY 10022	787024	36171623.04	69822989	06/22/2026	Nasdaq Stock Market
Common Stock	Morgan Stanley & Co. LLC 1585 Broadway New York NY 10036	46776	2149824.96	69822989	06/22/2026	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/23/2023	Merger	Issuer			833800	02/23/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
OrbiMed Private Investments VII, LP 601 Lexington Ave 54th Floor New York NY 10022	Common Stock	06/15/2026	272322	12259936.44

144: Remarks and Signature

Remarks	OrbiMed Capital GP VII LLC is the general partner of OrbiMed Private Investments VII, LP. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VII LLC.
Date of Notice	06/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Private Investments VII, LP
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)